CN113301903A - FcRn抗体的组合物及其使用方法 - Google Patents

FcRn抗体的组合物及其使用方法 Download PDF

Info

Publication number
CN113301903A
CN113301903A CN201980061788.8A CN201980061788A CN113301903A CN 113301903 A CN113301903 A CN 113301903A CN 201980061788 A CN201980061788 A CN 201980061788A CN 113301903 A CN113301903 A CN 113301903A
Authority
CN
China
Prior art keywords
amino acid
seq
formulations
pharmaceutical composition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980061788.8A
Other languages
English (en)
Chinese (zh)
Inventor
张钟利
格雷戈里·圣路易斯
E·威廉斯
N·辛赫
S·帕蒂尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CN113301903A publication Critical patent/CN113301903A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201980061788.8A 2018-07-20 2019-07-19 FcRn抗体的组合物及其使用方法 Pending CN113301903A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701467P 2018-07-20 2018-07-20
US62/701467 2018-07-20
PCT/US2019/042597 WO2020023310A1 (en) 2018-07-20 2019-07-19 Compositions of fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
CN113301903A true CN113301903A (zh) 2021-08-24

Family

ID=69180697

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980061788.8A Pending CN113301903A (zh) 2018-07-20 2019-07-19 FcRn抗体的组合物及其使用方法

Country Status (16)

Country Link
US (1) US20210299255A1 (enExample)
EP (1) EP3826641A4 (enExample)
JP (1) JP7457704B2 (enExample)
KR (1) KR20210105872A (enExample)
CN (1) CN113301903A (enExample)
AU (1) AU2019312139B2 (enExample)
BR (1) BR112021001017A2 (enExample)
CA (1) CA3106669A1 (enExample)
CR (1) CR20210088A (enExample)
EA (1) EA202190335A1 (enExample)
IL (1) IL280280B2 (enExample)
JO (2) JOP20210015A1 (enExample)
MX (1) MX2021000790A (enExample)
PH (1) PH12021550096A1 (enExample)
SG (1) SG11202100420UA (enExample)
WO (1) WO2020023310A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116539488A (zh) * 2023-05-11 2023-08-04 中国食品药品检定研究院 一种体外评价生物制品稳定性的方法、系统及设备

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64768B1 (sr) 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
IL302516A (en) * 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them
US20240182598A1 (en) * 2021-04-12 2024-06-06 Momenta Pharmaceuticals, Inc. Compositions and methods for treating pediatric myasthenia gravis
WO2024163894A1 (en) 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia
WO2025259928A1 (en) * 2024-06-13 2025-12-18 Obi Pharma, Inc. Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof
WO2026083290A1 (en) 2024-10-16 2026-04-23 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090131639A1 (en) * 2002-02-14 2009-05-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
CN103861102A (zh) * 2005-03-08 2014-06-18 辉瑞产品公司 抗ctla-4 抗体组合物
US20150157709A1 (en) * 2012-06-01 2015-06-11 Ophthotech Corporation Compositions Comprising an Anti-PDGF Aptamer and a VEGF Antagonist
US20150329628A1 (en) * 2012-12-18 2015-11-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
CN107567460A (zh) * 2015-01-30 2018-01-09 动量制药公司 Fcrn抗体及其使用方法
WO2018023136A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US20110027267A1 (en) * 2007-11-09 2011-02-03 Anaphore, Inc. Fusion Proteins of Mannose Binding Lectins for Treatment of Disease
WO2009124294A2 (en) 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
WO2017015622A2 (en) * 2015-07-22 2017-01-26 Scholar Rock, Inc Gdf11 binding proteins and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090131639A1 (en) * 2002-02-14 2009-05-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
CN103861102A (zh) * 2005-03-08 2014-06-18 辉瑞产品公司 抗ctla-4 抗体组合物
US20150157709A1 (en) * 2012-06-01 2015-06-11 Ophthotech Corporation Compositions Comprising an Anti-PDGF Aptamer and a VEGF Antagonist
US20150329628A1 (en) * 2012-12-18 2015-11-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
CN107567460A (zh) * 2015-01-30 2018-01-09 动量制药公司 Fcrn抗体及其使用方法
WO2018023136A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANN L DAUGHERTY AND RANDALL J MRSNY ED - STEVEN J SHIRE ET AL: "Formulation and Delivery Issues for Monoclonal Antibody Therapeutics", CURRENT TRENDS IN MONOCLONAL ANTIBODY DEVELOPMENT AND MANUFACTURING, pages 103 - 129 *
CHRISTENSEN, D ET AL.: "Trehalose preserves DDA/TDB liposomes and their adjuvant effect - during freeze-drying", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1768, no. 9, pages 2120 - 2129, XP022244079, DOI: 10.1016/j.bbamem.2007.05.009 *
MONTES, T ET AL.: "Genetic Modification of the Penicillin G Acylase Surface To Improve Its Reversible Immobilization on Ionic Exchangers", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 73, no. 1, pages 312 - 319, XP055039760, DOI: 10.1128/AEM.02107-06 *
NICHOLAS W WARNE ED - LENDLEIN ANDREAS ET AL: "Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 78, no. 2, pages 208 - 212, XP055534222, DOI: 10.1016/j.ejpb.2011.03.004 *
SHARMA V K ET AL: "The fomulation and delivery of monoclonal antibodies", THERAPEUTIC MONOCLONAL ANTIBODIES ： FROM BENCH TO CLINIC, pages 675 *
WHITTAKER, MM ET AL.: "Burst Kinetics and Redox Transformations of the Active Site Manganese Ion in Oxalate Oxidase: Implications for the Catalytic Mechanism", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, no. 10, pages 7011 - 7023, XP055682436, DOI: 10.1074/jbc.M609374200 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116539488A (zh) * 2023-05-11 2023-08-04 中国食品药品检定研究院 一种体外评价生物制品稳定性的方法、系统及设备
CN116539488B (zh) * 2023-05-11 2023-11-24 中国食品药品检定研究院 一种体外评价生物制品稳定性的方法、系统及设备

Also Published As

Publication number Publication date
IL280280B2 (en) 2024-11-01
AU2019312139A1 (en) 2021-02-04
JP7457704B2 (ja) 2024-03-28
WO2020023310A1 (en) 2020-01-30
JP2021531346A (ja) 2021-11-18
CA3106669A1 (en) 2020-01-30
IL280280A (en) 2021-03-25
MX2021000790A (es) 2021-07-21
JOP20210015A1 (ar) 2021-01-19
PH12021550096A1 (en) 2022-03-28
EP3826641A4 (en) 2022-04-20
IL280280B1 (en) 2024-07-01
AU2019312139B2 (en) 2025-02-06
KR20210105872A (ko) 2021-08-27
JOP20210014A1 (ar) 2021-01-19
US20210299255A1 (en) 2021-09-30
CR20210088A (es) 2021-09-02
BR112021001017A2 (pt) 2021-05-04
SG11202100420UA (en) 2021-02-25
EP3826641A1 (en) 2021-06-02
EA202190335A1 (ru) 2021-06-11

Similar Documents

Publication Publication Date Title
CN113301903A (zh) FcRn抗体的组合物及其使用方法
JP7599419B2 (ja) Ｆｃｒｎ抗体組成物
JP2024059765A (ja) Ｆｃｒｎ抗体及びその使用方法
KR102732284B1 (ko) 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
Yamniuk et al. Application of a kosmotrope-based solubility assay to multiple protein therapeutic classes indicates broad use as a high-throughput screen for protein therapeutic aggregation propensity
Liu et al. Analytical ultracentrifugation and its role in development and research of therapeutical proteins
BR112014021308B1 (pt) Formulações farmacêuticas de anticorpos
TW202039541A (zh) 多聚體ｔ細胞調節多肽及其使用方法
Yadav et al. Assessment and significance of protein–protein interactions during development of protein biopharmaceuticals
JP2023553209A (ja) 融合タンパク質の医薬製剤
EA046994B1 (ru) КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP4085253A1 (en) Deglycosylation methods for electrophoresis of glycosylated proteins
JP5205470B2 (ja) 免疫グロブリン凝集物
WO2023217294A1 (zh) 抗pd-1纳米抗体制剂及其用途
EA048285B1 (ru) Композиции антител против fcrn
BR112022025721B1 (pt) Formulação estável para anticorpo monoclonal anti-pd-1 recombinante
AU2024237533A1 (en) Antibody preparation
EP4210751A1 (en) Anti-ceruloplasmin antibodies and uses thereof
HK40022824A (en) Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: new jersey

Applicant after: MOMENTA PHARMACEUTICALS, Inc.

Address before: Massachusetts, USA

Applicant before: MOMENTA PHARMACEUTICALS, Inc.

Country or region before: U.S.A.

CB02 Change of applicant information